West Pharmaceutical's First Call Under New Management Is a Blowout — and a Test

A 12% organic quarter, a second guidance raise, and a new CEO promising closer customer ties; the HVP/GLP-1 engine is real, but so is the valuation.

WST · Earnings Call · 2026-10-29

The Blowout That Wasn't Supposed to Be a Surprise

West Pharmaceutical's Q3 was the kind of print a new CEO dreams about. Michel Lagarde, two months into the job, opened his first earnings call with a simple summary: “Revenues of $874 million grew 12% organically, and adjusted EPS of $2.66 was up 36% compared to last year.” — Michel Lagarde, President and Chief Executive Officer (CEO) · 2026-10-29 That EPS number was $0.47 above the midpoint of guidance. Management raised full-year revenue to $3.41–$3.42 billion and adjusted EPS to $9.38–$9.48, up from $8.85–$9.05. Organic growth guidance moved to 11.3%–11.6% from 10%–11%. The stock had already run 22.4% in the prior 90 trading days, so the market was leaning in; the report still cleared a high bar. Unlike the market's current obsession with AI data centers, West's catalyst is regulatory and mix-driven — a company-specific story, not a macro wave.

The Engine Is HVP, and It Is No Longer Just GLP-1

The core is HVP Components. Revenue of $467 million grew 20% organically and now represents 53% of the company. Bob McMahon called it "a standout" and pointed to “robust growth in biologics, continued strength in GLP-1, and positive HVP product mix shift.” — Bob McMahon, Senior Vice President and Chief Financial Officer (CFO) · 2026-10-29 The GLP-1 piece was just under 12% of total revenue and grew "well into the 30s" organically, an acceleration from the 27% discussed on the July call. Non-GLP HVP grew high teens. Price contributed just over four points. This matters because the bear case for years has been that West is a GLP-1 derivative. The quarter pushes back: the non-GLP HVP base is accelerating, and upgrade opportunity work is broadening. Management added over 200 upgrade projects this year and said Annex 1-style contamination rules are spreading beyond Europe. The U.S. HHS draft guidance is the live catalyst. Michel's framing: “It is quite logical for other regulators in the world to solve or focus on that same problem and suggest ways that companies need to comply.” — Michel Lagarde, President and Chief Executive Officer (CEO) · 2026-10-29 That is a multi-year regulatory tailwind, not a one-quarter product cycle. The prior calls show this has been building. In July, Eric Green said West had “just shy of 800 total projects in hand and that's up 50% from the same time period last year.” — Eric Green, Chief Executive Officer, Chair of the Board · 2026-07-23 In April, he sized the Annex 1 pool at six billion units: “we've identified at least 6 billion units that are targeted to be converted, and we're early in that stage.” — Eric Green, President, CEO and Chairman · 2026-04-23 The new information is geographic: the U.S. is now moving, not just Europe. Note the keyword set: Annex 1 regulations and the "bar on containment systems" are still present, but they have shifted from a top-line growth slogan to an embedded driver. That is what a maturing tailwind looks like.

The New CEO's Listening Tour — With a Subtle De-Emphasis

Lagarde did not announce a pivot. He spent most of his prepared remarks on culture, customers, and continuous improvement. He described West as on the "very short list of preferred partners" and argued the next leg is elevating customer relationships from operational to strategic. That is a softer message than the prior regime's operational-excellence mantra, but it is not a strategy change yet. The subtle shift is in the portfolio language. Lagarde said: “the core of it are its products” — Michel Lagarde, President and Chief Executive Officer (CEO) · 2026-10-29 and described West Vantage as "all about improving the business we have." In the prior four quarters, West Vantage and drug handling were pitched as growth vectors; in the current top-30 keyword set, West Vantage is absent, and drug handling is no longer a headline. That could simply reflect the CGM roll-off and the SmartDose divestiture cleaning up the story. But it also signals that the new CEO is not going to ask investors to underwrite a contract-manufacturing turnaround. The financial profile is the product business. M&A is the other tell. Lagarde was explicit:

The first focus will always be about continuing to strengthen the organic prospects of the company... the bar for M&A is incredibly high.
Michel Lagarde, President and Chief Executive Officer (CEO) · 2026-10-29

That is a conservative opening. It also fits the valuation: with the stock near a high and the organic engine running, there is no need to force a deal.

The Raise Is Real; the Price Is the Debate

The fundamental trajectory supports the narrative. Total revenue was $872 million in the June quarter, up 14% year over year. Operating margin was 20.6% in Q2, and the Q3 adjusted figure jumped to 25.3%, up 420 basis points. Gross margin was 39.7%, up 310 basis points. That is mix, price, and factory absorption all working at once. But the stock is no longer a sleepy compounder. Price to revenue is 7.6x, up 43% year over year, and price to net income is 44.7x. The 90-day tape shows a 22.4% run into the print, with the shares within 12% of their all-time high. The easy money was made on the anticipation; the next move depends on whether the earnings base keeps outrunning the multiple. There are two near-term brakes. Q4 organic growth is guided to 6%–7%, a step down from Q3's 12%, as West Vantage's Q3 pull-forward reverses and FX turns less helpful. A quarter ago, Bob McMahon was still framing guidance as “one quarter at a time and kind of a prudent approach” — Robert McMahon, Chief Financial Officer · 2026-07-23. And 2027 reported growth faces a roughly 290 basis point SmartDose headwind. Neither is a demand problem, but both will make the headline numbers look slower. The working-capital line is worth watching too: receivables are 81.6% of revenue, up 5.6 points year over year, and nine-month free cash flow was $278 million, down about 5%. Growth is consuming cash. The bull case is that HVP mix, Annex 1 upgrades, and finishing capacity additions keep the incremental margins high enough to justify the premium. The bear case is that the market has already capitalized the next two years of that story, and the new CEO's first priority is process, not a re-rating event. On the call, management called 2%–3% price the right planning assumption; that is prudent, but it also means the upside has to come from mix and volume, not pricing. The next real catalyst is February's 2027 guidance. If the company can guide through the SmartDose headwind and still show double-digit HVP growth with margin expansion, the premium is defensible. If not, this quarter will look like a well-timed peak in expectations rather than a new leg. For now, West has the rarest combination in medtech: a genuine secular upgrade cycle, a new CEO with an open field, and a stock that already knows it.